How long have we used RNA vaccines?
Answers from top 8 papers
More filters
| Papers (8) | Insight |
|---|---|
15 Citations | Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively. |
112 Citations | Because this approach uses RNA, it does not have the potential drawbacks of DNA vaccines and thus combines the advantages of conventional live virus vaccines (for example, mimicking natural infection and inducing long-lasting immunity) with those of nucleic acid-based vaccines (for example, ease of production without a requirement for eukaryotic cell culture, stability and purity). |
| As new cancer antigens come to the forefront with novel RNA encapsulation and targeting techniques, RNA vaccines may prove to be a vital, safe and robust method to initiate patient-specific anti-tumor efficacy. | |
394 Citations | Naked, non-infectious, self-replicating RNA may be an excellent candidate for the development of new cancer vaccines. |
15 Citations | This suggests that protein-based vaccines formulated using RNA adjuvant function as live-attenuated vaccines. |
126 Citations | Like other types of nucleic acid vaccines, mRNA vaccines have the potential to combine the positive attributes of live attenuated vaccines while obviating many potential safety limitations. |
30 Citations | RNA-based vaccines have important advantages over other vaccine approaches including outstanding efficacy, safety, and the potential for rapid, inexpensive, and scalable production. |
19 Oct 2017 161 Citations | Importantly, we show that the developed LNP-formulated mRNA vaccines can be used as a vaccination platform allowing multiple, sequential vaccinations against different pathogens. |